Scholarlink

Purpose <p>To evaluate the visual performance of a non-diffractive extended monofocal intraocular lens (Evolux™; SIFI, Catania, Italy) 12 months following cataract surgery.</p> Methods <p>This retrospective, non-randomized, single-arm study included 116 eyes from 82 patients who underwent cataract surgery with Evolux™ IOL implantation. Patients underwent preoperative and postoperative assessments including uncorrected and best-corrected distance (UDVA, CDVA) and near visual acuity (UNVA, CNVA), as well as refractive accuracy and defocus curve evaluation. Postoperative measurements were recorded at 1, 3, 6, and 12 months.</p> Results <p>At 12 months postoperatively, UDVA improved from 0.89 ± 0.54 logMAR to 0.10 ± 0.14 logMAR (<i>p</i> &lt; 0.001), and CDVA improved from 0.41 ± 0.40 logMAR to 0.04 ± 0.08 logMAR (<i>p</i> &lt; 0.001). 62% of eyes achieved a UDVA of 20/20 or better, while 96% reached at least 20/40. Refractive accuracy was high, with 76% of eyes achieving a postoperative spherical equivalent within ± 0.50 D and 95% within ± 1.00 D, indicating strong predictability. The defocus curve confirmed functional vision of 0.2 logMAR or better across a continuous defocus range of 2.00 D, supporting effective intermediate and near vision.</p> Conclusion <p>Evolux™ demonstrated good distance vision and enhanced intermediate vision without the visual disturbances commonly associated with multifocal or diffractive extended depth-of-focus IOLs. These findings suggest that Evolux™ is an effective solution for patients seeking greater spectacle independence and improved functional vision following cataract surgery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

12-month clinical outcomes of the Evolux™ extended monofocal intraocular lens following cataract surgery

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月30日

查看全文
  • Krešimir Gabrić,
  • Mateja Jagić,
  • Ivana Gabrić,
  • Maja Bohač

摘要

Purpose

To evaluate the visual performance of a non-diffractive extended monofocal intraocular lens (Evolux™; SIFI, Catania, Italy) 12 months following cataract surgery.

Methods

This retrospective, non-randomized, single-arm study included 116 eyes from 82 patients who underwent cataract surgery with Evolux™ IOL implantation. Patients underwent preoperative and postoperative assessments including uncorrected and best-corrected distance (UDVA, CDVA) and near visual acuity (UNVA, CNVA), as well as refractive accuracy and defocus curve evaluation. Postoperative measurements were recorded at 1, 3, 6, and 12 months.

Results

At 12 months postoperatively, UDVA improved from 0.89 ± 0.54 logMAR to 0.10 ± 0.14 logMAR (p < 0.001), and CDVA improved from 0.41 ± 0.40 logMAR to 0.04 ± 0.08 logMAR (p < 0.001). 62% of eyes achieved a UDVA of 20/20 or better, while 96% reached at least 20/40. Refractive accuracy was high, with 76% of eyes achieving a postoperative spherical equivalent within ± 0.50 D and 95% within ± 1.00 D, indicating strong predictability. The defocus curve confirmed functional vision of 0.2 logMAR or better across a continuous defocus range of 2.00 D, supporting effective intermediate and near vision.

Conclusion

Evolux™ demonstrated good distance vision and enhanced intermediate vision without the visual disturbances commonly associated with multifocal or diffractive extended depth-of-focus IOLs. These findings suggest that Evolux™ is an effective solution for patients seeking greater spectacle independence and improved functional vision following cataract surgery.